Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
landscape, with Eli Lilly ( NYSE:LLY ) and Novo Nordisk ( NYSE:NVO ) emerging as the two dominant forces in the category. A Lilly-funded head-to-head study published in 2025 showed Zepbound delivering stronger weight-loss outcomes than Novo's Wegovy, including greater waist reduction and a higher likelihood of patients losing at least 25% of their body weight over 72 weeks. That data has helped tilt near-term momentum toward Lilly, even as Novo appeared positioned to regain ground following regulatory approval of the first oral GLP-1 pill for weight loss, a development that could meaningfully broaden access as pills are expected to be cheaper than injections. Warning! GuruFocus has detected 1 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Both companies are also expanding beyond obesity into adjacent conditions, which could reinforce the long-term investment case. Wegovy remains the only GLP-1 drug proven to reduce heart attacks and o
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Health care will get more expensive for some in 2026 — and cheaper for others [MSNBC.com]MSNBC.com
- Novo Nordisk (CPSE:NOVO B) Is Up 9.0% After FDA Clears First Oral Wegovy Pill [Yahoo! Finance]Yahoo! Finance
- U.S. regulators approve Wegovy pill for weight loss [Los Angeles Times (CA)]Los Angeles Times
- Novo, Lilly race to cement lead in India's obesity drug market, Reuters says [Yahoo! Finance]Yahoo! Finance
- Health care will get more expensive for some in 2026 – and cheaper for others [MSNBC.com]MSNBC.com
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 12/23/25 - Form 6-K
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- NVO's page on the SEC website